Breast Cancer

Ruth O’Regan, MD, provides insight on how the COVID-19 crisis is impacting the care of patients with breast cancer.

In our exclusive interview, Dr. Hortobagyi shares his journey in the development of anthracyclines and taxanes, biphosphonates, and gene therapies in breast cancer, some of the challenges he has encountered along the way, and what he hopes to tackle in the rest of his monumental career.

Quantitative microelastography demonstrated increased sensitivity, specificity, and accuracy in detecting positive surgical margins in combination with optimal coherence tomography versus optimal coherence tomography alone in women who received breast-conserving surgery.

Lajos Pusztai, MD, DPhil, discusses the rationale for the phase 2 I-SPY 2 trial examining the addition of durvalumab and olaparib to neoadjuvant paclitaxel in HER2-negative breast cancer.

The addition of the novel innate immune activator, Imprime PGG, to checkpoint inhibition with pembrolizumab showed pronounced clinical benefit in patients with previously treated metastatic triple-negative breast cancer.

The addition of durvalumab (Imfinzi) and olaparib (Lynparza) to neoadjuvant paclitaxel was found to improve pathologic complete response rates compared with paclitaxel alone in patients with high-risk, HER2-negative stage II/III breast cancer.

Treatment with talazoparib did not demonstrate a statistically significant overall survival benefit in patients with BRCA1/2-mutated metastatic HER2-negative breast cancer.

Breast surgeon Kristin L. Brill MD, has joined the Sidney Kimmel Cancer Center – Jefferson Health as Enterprise Director of Breast Oncology.

In our exclusive interview, Aditya Bardia, MD, discusses the FDA approval of sacituzumab govitecan (Trodelvy) in metastatic triple-negative breast cancer.

Stephanie L. Graff, MD, director of the Breast Program at the Sarah Cannon Cancer Institute of HCA Midwest Health and associate director of the Breast Cancer Research Program at Sarah Cannon Research Institute, discusses the FDA approval of sacituzumab govitecan in metastatic triple-negative breast cancer (TNBC).

Melinda L. Telli, MD, discusses the role of PARP inhibition in the treatment of patients with breast cancer who harbor the BRCA mutations and ongoing research efforts seeking to expand their use beyond this setting.

Stephanie L. Graff, MD, discusses genomic risk prediction in patients with hormone receptor–positive, HER2-negative breast cancer.

This OncLive® webinar will focus on the impact of COVID-19 in patients with breast cancer and the innovative ways in which treatment has evolved during this time. Join us on May 7, 2020 at 8 PM EDT.